应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00512 远大医药
已收盘 05-02 16:08:16
4.460
+0.120
+2.76%
最高
4.460
最低
4.330
成交量
56.00万
今开
4.360
昨收
4.340
日振幅
3.00%
总市值
158.31亿
流通市值
158.31亿
总股本
35.50亿
成交额
247.27万
换手率
0.02%
流通股本
35.50亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
南向资金4月29日净买入远大医药123.35万股 连续3日增持
自选股智能写手 · 04-30 09:31
南向资金4月29日净买入远大医药123.35万股 连续3日增持
远大医药尾盘涨超5% 国产碳14同位素年底向市场供货
新浪港股 · 04-25
远大医药尾盘涨超5% 国产碳14同位素年底向市场供货
港股异动 | 远大医药(00512)盘中涨超6% 国产碳14同位素年底向市场供货 国产核药迎来新机遇
智通财经 · 04-25
港股异动 | 远大医药(00512)盘中涨超6% 国产碳14同位素年底向市场供货 国产核药迎来新机遇
远大医药(00512)上涨5.43%,报4.27元/股
金融界 · 04-25
远大医药(00512)上涨5.43%,报4.27元/股
远大医药盘中异动 急速上涨5.43%
自选股智能写手 · 04-25
远大医药盘中异动 急速上涨5.43%
港股概念追踪 |中国首次批量生产碳-14同位素 国产核药迎来新机遇(附概念股)
智通财经 · 04-22
港股概念追踪 |中国首次批量生产碳-14同位素 国产核药迎来新机遇(附概念股)
远大医药(00512.HK)获主席唐纬坤增持9.5万股
港股那点事 · 04-22
远大医药(00512.HK)获主席唐纬坤增持9.5万股
远大医药04月17日主力资金流出125万元 连续5日减仓
自选股智能写手 · 04-17
远大医药04月17日主力资金流出125万元 连续5日减仓
远大医药04月15日主力资金流出49万元 连续3日减仓
自选股智能写手 · 04-15
远大医药04月15日主力资金流出49万元 连续3日减仓
南向资金4月12日净买入远大医药167.40万股 连续3日增持
自选股智能写手 · 04-15
南向资金4月12日净买入远大医药167.40万股 连续3日增持
远大医药(00512)获执行董事、行政总裁周超增持10.10万股 每股作价约3.95港元
智通财经 · 04-10
远大医药(00512)获执行董事、行政总裁周超增持10.10万股 每股作价约3.95港元
远大医药盘中异动 大幅下跌5.16%报3.861港元
自选股智能写手 · 04-05
远大医药盘中异动 大幅下跌5.16%报3.861港元
远大医药(00512)下跌5.16%,报3.86元/股
金融界 · 04-05
远大医药(00512)下跌5.16%,报3.86元/股
远大医药03月28日主力资金流入15万元 连续3日加仓
自选股智能写手 · 03-28
远大医药03月28日主力资金流入15万元 连续3日加仓
远大医药(00512)布局全球创新眼科药物TP-03,或将填补国内蠕形螨睑缘炎治疗市场空白
智通财经 · 03-27
远大医药(00512)布局全球创新眼科药物TP-03,或将填补国内蠕形螨睑缘炎治疗市场空白
远大医药(00512)引进全球创新的治疗蠕形螨睑缘炎及蠕形螨导致的睑板腺功能障碍产品
智通财经 · 03-27
远大医药(00512)引进全球创新的治疗蠕形螨睑缘炎及蠕形螨导致的睑板腺功能障碍产品
远大医药(00512.HK)取得创新眼用制剂 “TP-03”大中华区独家授权 首付款1,500万美元
阿斯达克财经 · 03-27
远大医药(00512.HK)取得创新眼用制剂 “TP-03”大中华区独家授权 首付款1,500万美元
远大医药(00512)将于6月27日派发末期股息每股0.26港元
智通财经网 · 03-26
远大医药(00512)将于6月27日派发末期股息每股0.26港元
港股异动 | 远大医药(00512)最高涨超7% 放射性核素偶联药物国内III期临床获批
智通财经 · 03-26
港股异动 | 远大医药(00512)最高涨超7% 放射性核素偶联药物国内III期临床获批
港股异动 | 远大医药(00512)再涨超5% 治疗胃肠胰腺神经内分泌肿瘤新药获批III期临床
智通财经 · 03-26
港股异动 | 远大医药(00512)再涨超5% 治疗胃肠胰腺神经内分泌肿瘤新药获批III期临床
暂无数据
公司概况
公司名称:
远大医药
所属市场:
SEHK
上市日期:
--
主营业务:
远大医药健康控股有限公司是一家主要从事制造及销售医药制剂及医疗器械的香港投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械、生物技术产品及营养产品、精品原料药和其他产品。该公司的主要产品涵盖抗肿瘤、心血管急救制剂及高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科以及生物健康产品和精品原料药。
发行价格:
--
{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":4.46,"timestamp":1714637296024,"preClose":4.34,"halted":0,"volume":560000,"delay":0,"floatShares":3549571148,"shares":3549571148,"eps":0.535954,"marketStatus":"已收盘","marketStatusCode":5,"change":0.12,"latestTime":"05-02 16:08:16","open":4.36,"high":4.46,"low":4.33,"amount":2472651,"amplitude":0.029954,"askPrice":4.46,"askSize":4000,"bidPrice":4.44,"bidSize":500,"shortable":3,"etf":0,"ttmEps":0.535954,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714699800000},"adr":0,"listingDate":819302400000,"adjPreClose":4.34,"dividendRate":0.058296,"openAndCloseTimeList":[[1714613400000,1714622400000],[1714626000000,1714636800000]],"volumeRatio":0.136028,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512/tweets","defaultTab":"tweets","newsList":[{"id":"2431581800","title":"南向资金4月29日净买入远大医药123.35万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431581800","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431581800?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:31","pubTimestamp":1714440673,"startTime":"0","endTime":"0","summary":"4月29日, 南向资金增持远大医药123.35万股,连续3日增持。截止当日收盘,港股通共持有远大医药30733.56万股,占流通股8.65%。远大医药近5个交易日上涨9.02%,港股通累计增持100.90万股;近20个交易日上涨3.33%,港股通累计增持724.95万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300946048b6431c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300946048b6431c0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430424648","title":"远大医药尾盘涨超5% 国产碳14同位素年底向市场供货","url":"https://stock-news.laohu8.com/highlight/detail?id=2430424648","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2430424648?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:40","pubTimestamp":1714030845,"startTime":"0","endTime":"0","summary":"远大医药(00512)尾盘上涨5.19%,现报4.26港元,成交额2222.73万港元。\n 据“中核集团”官微发文,我国首次利用核电商用堆成功批量生产出碳-14同位素,标志着我国实现了碳-14供应的全面国产化。本次碳-14靶件完成出堆后,经后端处理后将于2024年底开始向市场供货,产量可充分满足国内需求,将有力带动我国同位素应用产业链发展,进一步建立健全产学研合作开展商用堆辐照生产同位素的研发体系,助推和牵引下游医疗企业高新型核药和核医疗产业研发,为国内同位素应用产业发展提供有力支撑。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-25/doc-inasztrw7499205.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-25/doc-inasztrw7499205.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430425809","title":"港股异动 | 远大医药(00512)盘中涨超6% 国产碳14同位素年底向市场供货 国产核药迎来新机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2430425809","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430425809?lang=zh_cn&edition=full","pubTime":"2024-04-25 14:22","pubTimestamp":1714026120,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,远大医药盘中涨超6%,截至发稿,涨4.94%,报4.25港元,成交额2111.59万港元。据悉,2023年,远大医药放射性核素偶联药物领域的重要战略合作伙伴Telix Pharmaceuticals Limited,向美国FDA递交了用于诊断肾透明细胞癌的全球创新RDC药物TLX250-CDx的生物制品上市许可申请。TLX250-CDx是一款全球创新的适用于 ccRCC 诊断的RDC药物,其靶点为碳酸酐酶 IX ,CA9 在 ccRCC 和其他许多癌种中过度表达。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109597.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430453164","title":"远大医药(00512)上涨5.43%,报4.27元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430453164","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430453164?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:22","pubTimestamp":1714015359,"startTime":"0","endTime":"0","summary":"4月25日,远大医药(00512)盘中上涨5.43%,截至11:22,报4.27元/股,成交1166.97万元。远大医药集团有限公司是一家专注于抗肿瘤、心血管急救制剂、高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科及生物健康产品和精品原料药的科技创新型国际化医药企业。公司在全球范围内布局了四个技术研发平台和五个研发中心,致力于成为一家受医生和患者尊重并还原于社会的科技创新型国际化医药企业。截至2023年年报,远大医药营业总收入95.42亿元、净利润17.04亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/25112240400672.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430443220","title":"远大医药盘中异动 急速上涨5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430443220","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430443220?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:22","pubTimestamp":1714015353,"startTime":"0","endTime":"0","summary":"2024年04月25日早盘11时22分,远大医药股票出现异动,股价快速拉升5.43%。截至发稿,该股报4.270港元/股,成交量276.8万股,换手率0.08%,振幅5.68%。资金方面,该股资金流入693.455万港元,流出292.392万港元。远大医药股票所在的药品行业中,整体涨幅为0.31%。其相关个股中,中国医疗集团、兴科蓉医药、石药集团涨幅较大,振幅较大的相关个股有联康生物科技集团、泰凌医药、和黄医药,振幅分别为12.35%、8.00%、7.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425112234861e8bdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240425112234861e8bdf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429696599","title":"港股概念追踪 |中国首次批量生产碳-14同位素 国产核药迎来新机遇(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2429696599","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429696599?lang=zh_cn&edition=full","pubTime":"2024-04-22 09:08","pubTimestamp":1713748107,"startTime":"0","endTime":"0","summary":"4月20日13时48分,经过两年的堆芯辐照后,第一根碳-14靶件从中核集团旗下中国核电投资控股的秦山核电重水堆机组中成功出堆,这是我国首次批量生产碳-14同位素,破解了国内碳-14同位素依赖进口的难题,实现碳-14供应全面国产化。碳-14是碳元素的一种具有放射性的同位素,被广泛作为示踪剂使用,幽门螺旋杆菌检测是其最具代表性的用途。此前,我国碳-14供应几乎全部依赖进口,价格昂贵且供应得不到保障,这已成为下游产业发展的制约因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106265.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429950655","title":"远大医药(00512.HK)获主席唐纬坤增持9.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429950655","media":"港股那点事","top":-1,"share":"https://www.laohu8.com/m/news/2429950655?lang=zh_cn&edition=full","pubTime":"2024-04-22 07:52","pubTimestamp":1713743539,"startTime":"0","endTime":"0","summary":"格隆汇4月22日丨根据联交所最新权益披露资料显示,2024年4月19日,远大医药(00512.HK)获执行董事兼主席唐纬坤在场内以每股均价3.91港元增持9.5万股,涉资约37.15万港元。增持后,唐纬坤最新持股数目为41.5万股。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-22/doc-inasryze2349661.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-22/doc-inasryze2349661.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428395878","title":"远大医药04月17日主力资金流出125万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428395878","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428395878?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:15","pubTimestamp":1713341728,"startTime":"0","endTime":"0","summary":"04月17日, 远大医药股价跌0.25%,报收3.96元,成交金额630万元,换手率0.04%,振幅1.76%,量比0.60。远大医药今日主力资金净流出125万元,连续5日净流出,上一交易日主力净流出207万元,今日环比减少39.61%。近一年数据显示,该股主力连续5日净流出后,次日下跌概率为33.33%,平均跌幅为0.98%。该股近5个交易日下跌2.94%,主力资金累计净流出489万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入347万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171615418b2df6c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171615418b2df6c4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427593025","title":"远大医药04月15日主力资金流出49万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2427593025","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427593025?lang=zh_cn&edition=full","pubTime":"2024-04-15 16:16","pubTimestamp":1713168970,"startTime":"0","endTime":"0","summary":"04月15日, 远大医药股价跌2.68%,报收3.99元,成交金额948万元,换手率0.07%,振幅2.93%,量比0.80。远大医药今日主力资金净流出49万元,连续3日净流出,上一交易日主力净流出69万元,今日环比减少28.99%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为64.29%,平均跌幅为1.37%。该股近5个交易日下跌0.50%,主力资金累计净流入364万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入684万元,其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415161634877e8e80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415161634877e8e80&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427948030","title":"南向资金4月12日净买入远大医药167.40万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427948030","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427948030?lang=zh_cn&edition=full","pubTime":"2024-04-15 09:31","pubTimestamp":1713144669,"startTime":"0","endTime":"0","summary":"4月12日, 南向资金增持远大医药167.40万股,连续3日增持。截止当日收盘,港股通共持有远大医药30236.36万股,占流通股8.51%。远大医药近5个交易日上涨6.77%,港股通累计增持181.10万股;近20个交易日上涨12.64%,港股通累计增持466.00万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415094430877cfbb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415094430877cfbb1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426827430","title":"远大医药(00512)获执行董事、行政总裁周超增持10.10万股 每股作价约3.95港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426827430","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426827430?lang=zh_cn&edition=full","pubTime":"2024-04-10 15:08","pubTimestamp":1712732918,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,4月8日,远大医药(00512)获执行董事、行政总裁周超增持10.10万股,每股作价3.9550港元,总金额为39.9455万港元。增持后最新持股数目26.30万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100505.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425304641","title":"远大医药盘中异动 大幅下跌5.16%报3.861港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425304641","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425304641?lang=zh_cn&edition=full","pubTime":"2024-04-05 11:34","pubTimestamp":1712288053,"startTime":"0","endTime":"0","summary":"2024年04月05日临近午盘11时34分,远大医药股票出现波动,股价快速下跌5.16%。截至发稿,该股报3.861港元/股,成交量61万股,换手率0.02%,振幅4.42%。资金方面,该股资金流入65.634万港元,流出164.53万港元。远大医药股票所在的药品行业中,整体跌幅为0.32%。其相关个股中,前海健康、三爱健康集团、天大药业涨幅较大,振幅较大的相关个股有三爱健康集团、康龙化成、复星医药,振幅分别为16.22%、9.71%、8.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405113413861e3829&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405113413861e3829&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425301095","title":"远大医药(00512)下跌5.16%,报3.86元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425301095","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425301095?lang=zh_cn&edition=full","pubTime":"2024-04-05 11:34","pubTimestamp":1712288053,"startTime":"0","endTime":"0","summary":"4月5日,远大医药(00512)盘中下跌5.16%,截至11:34,报3.86元/股,成交240.02万元。远大医药集团有限公司是一家专注于抗肿瘤、心血管急救制剂、高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科及生物健康产品和精品原料药的科技创新型国际化医药企业。公司在全球范围内布局了四个技术研发平台和五个研发中心,致力于成为一家受医生和患者尊重并还原于社会的科技创新型国际化医药企业。截至2023年年报,远大医药营业总收入95.42亿元、净利润17.04亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/05113440129246.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2422158021","title":"远大医药03月28日主力资金流入15万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2422158021","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422158021?lang=zh_cn&edition=full","pubTime":"2024-03-28 16:16","pubTimestamp":1711613762,"startTime":"0","endTime":"0","summary":"03月28日, 远大医药股价跌2.38%,报收4.11元,成交金额1085万元,换手率0.07%,振幅4.28%,量比0.41。远大医药今日主力资金净流入15万元,连续3日净流入,上一交易日主力净流入386万元,今日环比减少96.11%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为40.00%,平均涨幅为2.10%。该股近5个交易日上涨1.23%,主力资金累计净流入497万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入1556万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032816163687bfb9e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032816163687bfb9e4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422968584","title":"远大医药(00512)布局全球创新眼科药物TP-03,或将填补国内蠕形螨睑缘炎治疗市场空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2422968584","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422968584?lang=zh_cn&edition=full","pubTime":"2024-03-27 17:31","pubTimestamp":1711531875,"startTime":"0","endTime":"0","summary":"据悉,TP-03已于2023年7月获得美国FDA批准上市,是目前FDA批准的首款也是唯一一款针对蠕形螨睑缘炎的药物。TP-03或填补国内市场空白,惠及千万蠕形螨睑缘炎患者据悉,睑缘炎是一种常见的眼科疾病。因此,临床上急需一款起效快且可直接作用于病灶深部的安全有效的治疗药物,而远大医药此次布局的TP-03则有望填补这部分临床空白,为蠕形螨睑缘炎患者带来新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093423.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422683809","title":"远大医药(00512)引进全球创新的治疗蠕形螨睑缘炎及蠕形螨导致的睑板腺功能障碍产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2422683809","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422683809?lang=zh_cn&edition=full","pubTime":"2024-03-27 17:30","pubTimestamp":1711531853,"startTime":"0","endTime":"0","summary":"此外,TP-03在美国开展的用于治疗蠕形螨导致的睑板腺功能障碍的II期临床研究也显示出了阳性的顶线结果。本次交易完成后,集团将大力推进TP-03在中国的注册落地工作,尽早惠及广大蠕形螨睑缘炎患者。据统计,目前中国有超过4000万蠕形螨睑缘炎患者和超过7000万睑板腺功能障碍患者,患者人群庞大。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1093417.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422968840","title":"远大医药(00512.HK)取得创新眼用制剂 “TP-03”大中华区独家授权 首付款1,500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422968840","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422968840?lang=zh_cn&edition=full","pubTime":"2024-03-27 17:22","pubTimestamp":1711531320,"startTime":"0","endTime":"0","summary":"远大医药(00512.HK) 宣布,与联拓生物科技和Tarsus Pharmaceuticals, Inc.达成产品引进战略合作协议,在相关条件获得满足后,集团将以1,500万美元的首付款,以及一定金额的注册里程碑费用为代价,取得全球创新眼用制剂“TP-03”,在大中华区的独家开发、生产及商业化权益。集团表示,在交易完成后,将大力推进TP-03在中国的注册落地工作。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-27 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190311162624473_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190311162624473_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1337748/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422331664","title":"远大医药(00512)将于6月27日派发末期股息每股0.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422331664","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422331664?lang=zh_cn&edition=full","pubTime":"2024-03-26 18:05","pubTimestamp":1711447547,"startTime":"0","endTime":"0","summary":"远大医药(00512)发布公告,该公司将于2024年6月27日派发截至2023年1...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_48.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1092451.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422634070","title":"港股异动 | 远大医药(00512)最高涨超7% 放射性核素偶联药物国内III期临床获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2422634070","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422634070?lang=zh_cn&edition=full","pubTime":"2024-03-26 13:44","pubTimestamp":1711431898,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,远大医药最高涨超7%,截至发稿,涨6.58%,报4.21港元,成交额2122.16万港元。消息面上,近日,远大医药用于治疗胃肠胰腺神经内分泌瘤的全球创新放射性核素偶联药物 ITM-11已获得国家药监局批准开展III期临床研究。据悉,COMPOSE研究拟在中国、美国、英国、法国、德国、澳大利亚等全球11个国家入组至少202名患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1092191.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422638810","title":"港股异动 | 远大医药(00512)再涨超5% 治疗胃肠胰腺神经内分泌肿瘤新药获批III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2422638810","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422638810?lang=zh_cn&edition=full","pubTime":"2024-03-26 11:46","pubTimestamp":1711424771,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,远大医药早盘再涨超5%,绩后累涨约15%。截至发稿,涨5.06%,报4.15港元,成交额825.81万港元。消息面上,远大医药公布,集团用于治疗胃肠胰腺神经内分泌肿瘤的全球创新放射性核素偶联药物ITM-11,近日已获得中国国家药品监督管理局批准开展III期临床研究。董事会建议每股派息26港仙,总计分红约9.1亿港元,已连续分红6年,累计分红约28亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261148148b63a59a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403261148148b63a59a&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":0.0877},{"period":"1month","weight":0.056},{"period":"3month","weight":0.2878},{"period":"6month","weight":0.0458},{"period":"1year","weight":-0.1227},{"period":"ytd","weight":0.0611}],"compareEarnings":[{"period":"1week","weight":0.0555},{"period":"1month","weight":0.0739},{"period":"3month","weight":0.1471},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.1071},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药健康控股有限公司是一家主要从事制造及销售医药制剂及医疗器械的香港投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械、生物技术产品及营养产品、精品原料药和其他产品。该公司的主要产品涵盖抗肿瘤、心血管急救制剂及高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科以及生物健康产品和精品原料药。","yearOnYearQuotes":[{"month":1,"riseRate":0.482759,"avgChangeRate":0.094346},{"month":2,"riseRate":0.689655,"avgChangeRate":0.105408},{"month":3,"riseRate":0.37931,"avgChangeRate":0.012932},{"month":4,"riseRate":0.62069,"avgChangeRate":0.018409},{"month":5,"riseRate":0.428571,"avgChangeRate":0.068711},{"month":6,"riseRate":0.357143,"avgChangeRate":-0.049881},{"month":7,"riseRate":0.392857,"avgChangeRate":-0.01429},{"month":8,"riseRate":0.392857,"avgChangeRate":0.004418},{"month":9,"riseRate":0.464286,"avgChangeRate":-0.045547},{"month":10,"riseRate":0.535714,"avgChangeRate":-0.01036},{"month":11,"riseRate":0.535714,"avgChangeRate":0.091557},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008312}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}